- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03485547
Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
This research study is studying a drug as a possible treatment for BPDCN.
The intervention involved in this study is: Venetoclax
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the safest dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved venetoclax for this specific disease but it has been approved for other uses.
Based on laboratory data where it was found that BPDCN cells die after treatment with Venetoclax, the investigators believe that this drug will be effective in treating patients with BPDCN.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) per 2016 WHO criteria
- Age > 18 years
- In Stage 1 (modified 3+3): BPDCN relapsed after or refractory to at least one prior treatment regimen (hydroxyurea is not considered a prior treatment regimen)
In Stage 2 (expansion):
(A) BPDCN relapsed after or refractory to at least one prior treatment regimen (hydroxyurea is not considered a prior treatment regimen)
---OR
- (B) Treatment-naïve BPDCN, and age > 75 years; or treatment-naïve BPDCN, and age > 18 years and who decline intensive induction chemotherapy or who are unfit due to co-morbidity or other factors (see APPENDIX A for unfitness definitions)
- ECOG performance status 0, 1, or 2
Adequate organ function as defined by:
- Serum creatinine < 1.5x ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5x ULN
- Total bilirubin < 1.5x ULN (if total bilirubin is > 1.5x but < 3x ULN, and thought to be elevated due to Gilbert's disease or the patient's BPDCN, the subject may be eligible but must discuss with the PI)
- Ability to understand and the willingness to sign a written informed consent document.
- Able to adhere to study visit schedule and other protocol requirements including follow-up for survival assessment
- Women of child-bearing potential and men enrolled on this protocol must agree to use adequate contraception for the duration of study participation and for 2 months after completion venetoclax administration.
Exclusion Criteria:
- Prior treatment with venetoclax
- Received treatment with chemotherapy, radiation, or biologic cancer therapy within 14 days of first protocol treatment. Prior and concurrent hydroxyurea is permitted during the first cycle.
- Hematopoietic stem cell transplantation (HSCT) within 60 days of first protocol treatment, or receipt of immunosuppressive therapy for graft-versus-host disease treatment or prophylaxis within 14 days of first protocol treatment, or active graft-versus-host-disease
- Known active CNS involvement by BPDCN
- Known positive status for HIV infection; known active hepatitis B or hepatitis C infection
- Clinically significant cardiopulmonary disease including uncontrolled or NYHA class 3 or 4 congestive heart failure, uncontrolled angina, uncontrolled hypertension, uncontrolled arrhythmia, myocardial infarction or stroke within 6 months of first protocol treatment
- Patients with known active advanced malignant solid tumors are excluded (except for basal or squamous skin cancers, or carcinomas in situ). Patients with additional hematologic malignancies that require treatment are excluded.
- Patients with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)
- Pregnant women are excluded from this study because there is an unknown but potential risk for adverse events in the developing fetus with venetoclax (negative urine or serum pregnancy test required within 14 days of Cycle 1, Day 1). Because nursing infants have unknown potential for adverse events secondary to treatment of the mother, breastfeeding should be discontinued if the mother is treated with venetoclax.
- Infection is a common feature of BPDCN and acute leukemias. Patients with active infection are permitted to enroll provided that the infection is controlled (patients on IV or PO antibiotics are allowed). Patients with uncontrolled infection shall not be enrolled until infection is treated and brought under control.
Subject has received the following within 7 days prior to the initiation of study treatment:
- Strong and moderate CYP3A inducers
- Strong and moderate CYP3A inhibitors
- Subject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or Star fruit within 3 days prior to the initiation of study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Venetoclax
|
VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis.
Through apoptosis, your body allows cancer cells and normal cells to self-destruct
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose Limiting Toxicity
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival
Time Frame: 2 years
|
2 years
|
Progression free survival
Time Frame: 2 years
|
2 years
|
Overall Response Rate
Time Frame: 2 years
|
2 years
|
Complete Response
Time Frame: 2 years
|
2 years
|
Partial Response
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Andrew Lane, MD, Dana-Farber Cancer Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-045
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blastic Plasmacytoid Dendritic Cell Neoplasm
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBlastic Plasmacytoid Dendritic Cell NeoplasmUnited States
-
Samsung Medical CenterCompletedBlastic Plasmacytoid Dendritic Cell NeoplasmKorea, Republic of
-
Immune Oncology Research InstituteRecruitingBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)United States, Armenia, Canada, Egypt, Georgia, United Kingdom, Cyprus, Italy, Turkey, India, Iraq, Taiwan, Kuwait
-
Centre Hospitalier Universitaire de BesanconCentre Hospitalier Universitaire Dijon; Centre Henri Becquerel; Maisonneuve-Rosemont... and other collaboratorsActive, not recruitingBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)France
-
Mustang BioTerminatedBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBlastic Plasmacytoid Dendritic Cell NeoplasmUnited States
-
Cellectis S.A.TerminatedBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)United States
-
Centre Hospitalier Universitaire de BesanconCompletedBlastic Plasmacytoid Dendritic Cell Neoplasm | Hematological Malignancies
-
AvenCell Europe GmbHPHARMALOG Institut für klinische Forschung GmbHRecruitingBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Acute Myeloid Leukemia (AML)Germany
-
ImmunoGen, Inc.Active, not recruitingBlastic Plasmacytoid Dendritic Cell Neoplasm | Myeloproliferative NeoplasmUnited States, Spain, Germany, Italy, France, United Kingdom
Clinical Trials on Venetoclax
-
Virginia Commonwealth UniversityAbbVieWithdrawnRelapsed Small Cell Lung Cancer | Refractory Small Cell Lung Carcinoma
-
University of Maryland, BaltimoreActive, not recruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States
-
Yale UniversityCompleted
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic CLL Study GroupActive, not recruitingChronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in RemissionNetherlands, Belgium, Denmark, Finland, Norway, Sweden
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic Lymphoma GroupActive, not recruiting
-
The Lymphoma Academic Research OrganisationInstitute of Cancer Research, United KingdomRecruitingMantle Cell LymphomaFrance, United Kingdom, Belgium
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingChronic Lymphocytic LeukemiaUnited States
-
BioSight Ltd.Recruiting